Close Menu

NEW YORK (GenomeWeb) – Tangen Biosciences today announced that it has closed a $9 million Series A equity financing round and will use the proceeds to develop its TangenDx platform for two undisclosed infectious disease tests performed in the clinic.

Tangen said that its platform employs rapid isothermal nucleic acid detection of targeted DNAs and RNAs directly from specimens. The platform may enable use of low cost, portable, and rapid MDx diagnostic capabilities outside traditional laboratories, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.